Pike et al. Deucravactinib (TYK2i) in SLE. + on SRI(4) week 32. + SRI(4),BICLA, LLDAS, CLASI-50, swollen and tender joint counts week 48. Strange, the lowest dose (3mg bd) seems best. @RheumNow #ACR22 Abstr#1117 #ACRbest https://t.co/o4902tvZs8 https://t.co/t8oeMRGUS7

• Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inh…

@RheumNow interview with Dr. Lauren Smith on race differences in MMF responses in systemic sclerosis at #ACR22 @jhrheumatology @JHRheumFellows https://t.co/aSRHiJoIkE

Karmacharya et al. Multimorbidity in PsO strongly influences incident PsA, >=2 comorbidities HR 2.53, >=5 comorbidities HR 3.19. Also higher for non-white, HR 4.02, and decreased with age. @RheumNow #ACR22 Abstr#1506 https://t.co/OFobRzhQVL https://t.co/IP08XlD66H

• Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Populat…

2000 IU/day vitamin D led to significantly reduced incidence of autoimmune diseases in Abs 1200 over 5.3 years, but after trial termination, protective effects dissipated and were no longer significant. #ACR22 @RheumNow https://t.co/sLwoxeCR3y https://t.co/47wpWXF1W7

• Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmun…

HCQ does not prevent RA in CCP+ pts w/out clinical arthritis! Stop RA: RCT HCQ vs. PBO in pts at-risk Interim analysis 140+ pts RA development HCQ 34% vs. PBO 36% Trial interrupted as met futility criteria. https://t.co/n31OmsjLhM Abs#1604 #ACR22 @RheumNow #ACRBest https://t.co/NVYS8kB5to

• Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthri…

2022 ACR G/L for Integrative RA Intervent #ACR22 1 strong rec: consistent exercisee 27 conditional recs: Rehab, Mediterr diet, against other diets, self-mgmt/CBT/acupunct Conditional against electrotherapy, chiropractor No rec for diet supplem BMI, 🚬: no RA spec recomm @RheumNow https://t.co/cVFr6beQuJ

Patel @draditipatel et al. Delay in starting ACE-I in Scleroderma Renal Crisis increased need for dialysis 75.6% vs 16.7%, p=0.023. No effect on overall survival. 5-year mortality 70%, 1 year mortality 58%. @RheumNow #ACR22 Abstr#1530 https://t.co/cdYhEtqcHT https://t.co/lDWJto1cF0

• Scleroderma Renal Crisis: Time to Initiation of Therapy Does Not Affect Mortali…

Mease et al. PsA - Early DMARD initiators (=<1 year following diagnosis) greater improvement in outcomes than late initiators (at least in MDA) in CorEvitas. @RheumNow #ACR22 Abstr#1493 https://t.co/oadxbG8TKS https://t.co/245xVTcKx1

• Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs…

Nabi. Biosimilar to biosimilar IFX switch in DANBIO. High retention rate - 92% in originator-experienced equiv to normal drop off at 1 year on a biologic. Lower retention 83% in originator-naive switchers = likely nocebo effect @RheumNow #ACR22 Abstr#1112 https://t.co/oa1SawWWs4 https://t.co/iU3doB9jV4

• Biosimilar-to-Biosimilar Switching in Routine Care – Results on &gt;1,600 Patie…

New biomarkers of increased disease activity in PsA? Tissue remodeling and inflammation (neutrophil activity and fibrosis) biomarkers showed best performance in differentiating PsA w/ flares and without. Abs#1610 @RheumNow #ACR22 https://t.co/73ta7VXgTY

Kiltz et al. Greater efficacy of secukinumab in normal BMI than high BMI AS patients. Decremental effect with increasing BMI. @RheumNow #ACR22 Abstr#1495 https://t.co/zwEmQsJmPT https://t.co/nOW2IbTc5t

• How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Pa…

Dörner et al. Remibrutinib (BTKi) in pSS. + study in pSS! Improved ESSDAI (disease activity), no effect ESSPRI (PRO), trend to improve salivary flow, + effect on multiple labs. @RheumNow #ACR22 Abstr#1113 https://t.co/m2rvXbqq7b https://t.co/jQLyP66zX9

• Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a…

Benesova et al. Higher treatment response to secukinumab in both male and female AS patients when diagnosed earlier. No such effect seen in PsA patients. Emphasises need to reduce diagnostic delay in AS. @RheumNow #ACR22 Abstr#1497 https://t.co/9g2zN85a33 https://t.co/LfvQFTKr69

• How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients wit…

Promising results for Izokibep in PsA Ph2 RCT meets primary endpoint at Wk 16 ACR50: 13% PBO 48% 40mg IZO 52% 80mg IZO MDA: 5% PBO 42% 40mg 39% 80mg Results observed as soon as wk2 No new safety signal compared to IL17Ai https://t.co/Gilhg5k36b Abs#1597 #ACR22 @RheumNow https://t.co/VvxSRLtkFk

• Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy …

Protective effect of #allopurinol in gout Dose dependent reduction in risk of acute coronary syndrome in incident #Gout #ACR22 @RheumNow abst#1582 https://t.co/PrEtRwvLvm